Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib
Andrea M. Gross, Olivia H. Reid, Bruce R. Korf, Ashley Cannon et al.
Citations
2 citations
Journal
JAMA Dermatology
Topics
Neurofibromatosis and Schwannoma Cases
Field-Weighted Citation Impact (FWCI)
2.78
article
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib
Andrea M. Gross, Olivia H. Reid, Bruce R. Korf, Ashley Cannon, Lauren Baldwin, Cecilia Tibery, Mina Lobbous, Seth M. Steinberg, Dominique C. Pichard, Eva Dombi, Joanne Derdak, Pamela L. Wolters, Brigitte C. Widemann, Hyoyoung Choo‐Wosoba
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
JAMA DermatologyVol. 161(5)
Institutions
Leidos (United States) (US), National Institutes of Health (US), University of Alabama at Birmingham (US), National Institute of Arthritis and Musculoskeletal and Skin Diseases (US), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (US), National Center for Advancing Translational Sciences (US), Center for Cancer Research (US), Leidos Biomedical Research Inc. (United States)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib — Andrea M. Gross, Olivia H. Reid, et al. · JAMA Dermatology (2025) | TGRS Research Map | TGRS